Frickenhausen – Greiner Bio-One, a leading international technology partner for the diagnostic and pharmaceutical industry, presents the 96 well CrystalQuick X plate. This microplate is the first of its kind to be specifically tailored to

the requirements of X-ray structure analysis of protein crystals directly in the plate.

It is also optimal for UV screening of crystals.

The new microplate dramatically improves the results of in-situ crystal analyses. Its open geometry allows data to be collected directly in the plate within an angular range of up to 80°. An ultra-thin-walled well bottom minimises background scattering significantly. Thanks to the excellent optical properties of CrystalQuick X, the new microplate is ideal for brightlight microscopy as well as applications involving polarised and UV light.

With two flat-bottom crystallisation wells per reservoir, CrystalQuick X makes it possible to test 192 sitting drop samples per plate. The plate features alphanumeric well coding and an additional scale (0.1 x 0.5 mm) which enables the quick estimation of crystal size. The footprint of CrystalQuick X conforms with the ANSI/SBS 1-2004 standard. The plate is therefore compatible with all conventional automatic systems.

Greiner Bio-One developed this new 96 well microplate in collaboration with Beamline FIPBM30A (European Synchrotron Radiation Facility, ESRF, Grenoble, France). Crystal- QuickTMX is part of the CrystalStarTM product line from Greiner Bio-One GmbH.

Greiner Bio-One GmbH – BioScience Division

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory equipment.

The company is technology partner for universities, research institutes and the diagnostic, pharmaceutical and biotechnology

industries as well. With the BioScience division, Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures, as well as microplates for highthroughput screening, allowing industry and research most rapid and efficient drug screening. Additionally Greiner Bio-One develops innovative biochip technologies for genotyping.

Under the management of Heinz Schmid, the German headquarters of the BioScience division in Frickenhausen (Baden-Württemberg) controls the whole research and development activities in the product ranges Cell Culture, High-Throughput Screening, Biochips and OEM. Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 278.6 million Euro. It has over 1,500 employees and operates globally with 19 own subsidiaries and numerous distributors in more than 100 countries.